FIELD: medicine.
SUBSTANCE: invention relates to a method for the treatment of cancer with TP54 of a wild type, including the injection of HDM201 in two different injection days within a treatment cycle, where the first injection day and the second injection day are separated by a short period without injection, and the second injection day of the first or earlier treatment cycle and the first injection of the following cycle are separated by an extended period without the injection, where the short period without the injection consists of 4-8 days, and the extended period without the injection consists of 13-27 days, and where the treatment consists of at least 2 treatment cycles, while the daily dose in injection days is from 100 to 200 mg.
EFFECT: claimed method allows for the injection of a high dose providing the efficiency and the reduction in the risk of undesired occurrences.
9 cl, 8 dwg, 17 tbl, 5 ex
| Title | Year | Author | Number |
|---|---|---|---|
| DOSE AND SCHEME OF INJECTION OF AN INHIBITOR OF INTERACTION OF HDM2 WITH p53 IN HEMATOLOGICAL TUMORS | 2018 |
|
RU2753527C2 |
| HDM2-P53 INHIBITOR AND BCL2 INHIBITOR INTERACTION COMBINATIONS AND THEIR USE FOR CANCER TREATMENT | 2019 |
|
RU2793123C2 |
| DISCONTINUOUS INTRODUCTION OF MDM2 INHIBITOR | 2015 |
|
RU2695228C2 |
| GDF-15 AS A HAEMATOLOGICAL TOXICITY BIOMARKER | 2016 |
|
RU2741390C2 |
| DOSAGE REGIMEN FOR AN ALPHA-ISOFORM SELECTIVE PHOSPHATIDYLINOSITOL 3-KINASE INHIBITOR | 2014 |
|
RU2680246C1 |
| DOSING REGIMES OF MELFLUFEN FOR CANCER DISEASES | 2016 |
|
RU2734930C2 |
| MDM2 AND P53 INTERACTION INHIBITORS | 2007 |
|
RU2436784C2 |
| DUAL ATM AND DNA-PK INHIBITORS FOR ANTITUMOR THERAPY | 2020 |
|
RU2800756C1 |
| COMBINATION THERAPY FOR CANCER TREATMENT | 2014 |
|
RU2805145C2 |
| COMBINATION THERAPY FOR TREATMENT OF CANCER | 2014 |
|
RU2680714C2 |
